We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Advanced Medical Solutions Group Plc | LSE:AMS | London | Ordinary Share | GB0004536594 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
6.00 | 3.16% | 196.00 | 195.00 | 196.00 | 197.40 | 189.20 | 190.20 | 780,056 | 16:35:15 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Plastics,resins,elastomers | 124.33M | 20.41M | 0.0939 | 20.81 | 424.43M |
TIDMAMS
RNS Number : 5105C
Advanced Medical Solutions Grp PLC
13 April 2017
13 April 2017
Advanced Medical Solutions Group plc
("AMS", the "Company" or the "Group")
Director/PDMR and PCA Shareholding
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), a leading developer and manufacturer of advanced products for the global surgical and wound care markets, announces that it was notified on 11 April 2017 that Jeff Willis, who is a Senior Manager and PDMR, had sold 100,000 Ordinary Shares of 5p on 10 April 2017.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1. Details of the person discharging managerial responsibilities/person closely associated --- -------------------------------------------------- a) Name: Jeff Willis --- -------------------------------------------------- 2. Reason for the notification --- -------------------------------------------------- a) Position/status: PDMR --- -------------------------------------------------- b) Initial notification/Amendment: Initial Notification --- -------------------------------------------------- 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor --- -------------------------------------------------- a) Name: Advanced Medical Solutions Group plc --- -------------------------------------------------- b) LEI: 213800HJP6OWOSZI1L74 --- -------------------------------------------------- 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted --- -------------------------------------------------- a) Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 --- -------------------------------------------------- b) Nature of the transactions: * Sale of 100,000 Ordinary Shares of 5p --- -------------------------------------------------- c) Price(s) and volume(s): Sale of shares: Price(s) Volume(s) ----------- ---------- GBP2.6025 100,000 ----------- ---------- --- -------------------------------------------------- d) Aggregated information: (Relates to those shares sold only) Aggregated volume: 100,000 Aggregated price: GBP2.6025 --- -------------------------------------------------- e) Date of the transaction: 10/04/2017 --- -------------------------------------------------- f) Place of the transaction: London Stock Exchange, AIM Market (XLON) --- --------------------------------------------------
- End -
For further information, please visit www.admedsol.com or contact:
Advanced Medical Solutions Group Tel: +44 (0) plc 1606 545508 Chris Meredith, Chief Executive Officer Mary Tavener, Chief Financial Officer Consilium Strategic Communications Tel: +44 (0) 20 3709 5700 Mary-Jane Elliott / Jonathan AMS@consilium-comms.com Birt / Matthew Neal / Hendrik Thys Investec Bank plc (NOMAD & Broker) Tel: +44 (0) 20 7597 5970 Daniel Adams / Patrick Robb
About Advanced Medical Solutions Group plc - see www.admedsol.com
AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and advanced wound care markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of wound care products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it sells under white label as well as its own brand ActivHeal(R) , and surgical tissue adhesives, sutures and haemostats, which markets under its own brands; LiquiBand(R) and RESORBA(R) .
AMS's products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in more than 70 countries via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia. Established in 1991, the Company has 600 employees. For more information, please see www.admedsol.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHBLGDSLDBBGRX
(END) Dow Jones Newswires
April 13, 2017 12:30 ET (16:30 GMT)
1 Year Advanced Medical Solutions Chart |
1 Month Advanced Medical Solutions Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions